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Abstract: With brain tumour incidence increasing, there is an urgent need for better diagnostic
tools. Intraoperatively, brain tumours are diagnosed using a smear preparation reported by a
neuropathologist. These have many limitations, including the time taken for the specimen to reach the
pathology department and for results to be communicated to the surgeon. There is also a need to assist
with resection rates and identifying infiltrative tumour edges intraoperatively to improve clearance.
We present a novel study using a handheld Raman probe in conjunction with gold nanoparticles,
to detect primary and metastatic brain tumours from fresh brain tissue sent for intraoperative smear
diagnosis. Fresh brain tissue samples sent for intraoperative smear diagnosis were tested using the
handheld Raman probe after application of gold nanoparticles. Derived Raman spectra were inputted
into forward feature extraction algorithms to build a predictive model for sensitivity and specificity of
outcome. These results demonstrate an ability to detect primary from metastatic tumours (especially
for normal and low grade lesions), in which accuracy, sensitivity and specificity were respectively
equal to 98.6%, 94.4% and 99.5% for normal brain tissue; 96.1%, 92.2% and 97.0% for low grade
glial tumours; 90.3%, 89.7% and 90.6% for high grade glial tumours; 94.8%, 63.9% and 97.1% for
meningiomas; 95.4%, 79.2% and 98.8% for metastases; and 99.6%, 88.9% and 100% for lymphoma,
based on smear samples (κ = 0.87). Similar results were observed when compared to the final
formalin-fixed paraffin embedded tissue diagnosis (κ = 0.85). Overall, our results have demonstrated
the ability of Raman spectroscopy to match results provided by intraoperative smear diagnosis and
raise the possibility of use intraoperatively to aid surgeons by providing faster diagnosis. Moving this
technology into theatre will allow it to develop further and thus reach its potential in the clinical arena.
Keywords: brain tumour diagnosis; classification; forward feature extraction algorithm; intraoperative
use; Raman spectroscopy; Raman probe
1. Introduction
Brain tumours account for 3% of all tumours diagnosed annually [1]. Whilst this comprises a
small proportion of total cancer burden, the difficulty of complete removal of the tumour is inherent.
High-grade tumours can be infiltrative and when operating within the brain the risk of removing
crucial structures in a bid to free the patient of the tumour, yet risk leaving them with significant
neural deficit is ever present. Up to 75% of tumour resections are thought to leave behind viable
tumour, though there is a survival benefit to improved/complete resection [2,3]. Therefore, any new
technique available to highlight residual tumour, thus improving outcome and resection, yet reducing
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the non-tumour tissue removed would be beneficial. Currently, the use of 5-aminolevulinic acid
(5-ALA) does allow for fluorescence of tumour cells in order to aid resection; however, this is imperfect.
It can be difficult to tell apart tumour from background fluorescence [4].
In recent years many studies have been performed using vibrational spectroscopy in an effort to
improve and decrease time to cancer diagnosis and aid resection of tumours. Vibrational spectroscopy
includes two complementary techniques: Raman and attenuated total reflection Fourier-transform
infrared (ATR-FTIR) spectroscopy. Raman spectroscopy detects chemical bonds via scattering of
photons due to bond vibrations, whereas ATR-FTIR spectroscopy measures energy absorbance after
excitation by an IR beam following reflection of the beam via an internal element (usually crystal) [5].
Both generate a ‘fingerprint’ of the elements within the examined sample, which can be examined to
determine differences between them [5]. The majority of these studies have been ex vivo, with a move
in recent years to increase the number of in situ studies [6], though these have yet to demonstrate
definitive results. The need to test fresh tissue is crucial, to overcome any spectral changes seen due to
formalin fixation or freezing artefact [7,8]. The use of gold nanoparticles in conjunction with Raman
spectroscopy, known as surface enhanced Raman scattering (SERS) has previously been shown to
improve the Raman signal received, reducing signal-to-noise ratio (SNR) and thus enhance the spectral
quality [9]. This method uses molecules adsorbed onto the target surface prior to spectral acquisition,
it has previously shown promise when used particularly with blood products to detect cancer [10].
The ability to use a probe intraoperatively, for example in brain surgery, and tell the surgeon in
real-time if the tissue is cancerous or not would be greatly beneficial and perhaps the most useful area
for Raman spectroscopy to make its clinical entry. Many areas within the cancer care pathway have
been considered for targeting by spectroscopy, yet this is likely to be the best target location [10,11].
Stables et al. proposed a sound method to enable the surgeon to detect differences in the brain tissue
found using spectroscopy as a method to provide real-time feedback [12]. This is an interesting
suggestion, and certainly there is a need to develop technology to provide the surgeon with an answer
without the need to interpret spectra. Desroches et al. used a handheld Raman probe intraoperatively
with an accuracy of 87% to determine brain tumour from non-tumour tissue [13]. They then followed
the study with the development of an optical biopsy needle for use during brain tumour biopsies.
Following validation in an animal model, they tested their system during human brain surgery with
an accuracy of 84%, sensitivity of 80% and specificity of 90% for tumour detection. These results
were from comparing Raman spectra to biopsy results where the majority of the biopsy comprised
tumour tissue [14]. This shows exciting potential; however, due to light contamination much of their
study required procedures to be performed in darkness. Other types of Raman probes, such as based
on stimulated Raman scattering, have been used in many biological applications, in particular for
intracellular sensing and imaging [15].
Handheld probes have also been used for lymph node, breast and cervical testing. Horsnell et al.
demonstrated that a handheld Raman probe used to determine the presence of cancer within sentinel
lymph nodes with suspected breast cancer metastasis. They achieved sensitivities and specificities
of up to 92% and 100% respectively, using frozen tissue [16]. They then went on to test lymph nodes
using Raman micro-spectroscopy, and achieved concordance with histopathology in up to 91% of cases,
improving as more points were assessed [17]. Within breast pathology, Haka et al. demonstrated a 93%
accuracy in determining normal breast from benign or cancerous lesions [18]. They also demonstrated
the potential of using Raman spectroscopy for intraoperative assessment of mastectomy margins with
positive results, and possibly may have improved intraoperative results had spectroscopy been used
in real-time [19]. As Raman spectroscopy is unaffected by aqueous materials therefore it is felt by the
authors to be most suited to examining fresh brain tissue.
This study has been designed in order to determine the potential of the use of intraoperative SERS
for brain tumour diagnosis within the neuropathology department. Raman spectral analysis of fresh
brain tissue sent for intraoperative smear diagnosis was performed. The objective was to compare
SERS results to both the intraoperative smear result and final formalin-fixed paraffin embedded tissue
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(FFPE) result. This was done to understand if SERS can aid the clinical pathway and provide results
similar to conventional neuropathology, with the aim of replacing the need for an intraoperative smear
diagnosis, allowing the surgeon to test tissue intraoperatively to guide diagnosis and resection in
the future.
2. Materials and Methods
Prior to using the handheld Raman machine, a custom-built box (sample compartment) was
required to ensure darkness when analysing the tissues. As this was being placed into a working
laboratory, it would not be possible to work in darkness and it would also need to fit into a category 2
fume hood for work with fresh tissue. With this is mind, a box was custom engineered using plywood.
A stage was built within this box to allow the slide to be moved in the x and y planes with a custom
cut out area for the slide to be held securely. This was to allow the tissue to be accurately positioned
under the probe. A clamp was then secured to the box to allow the probe to be moved in the z plane
to allow it to be positioned at the correct height above the tissue. Thus allowing movement similar
to a conventional light microscope. The box was painted with black paint on the inside to minimise
reflection of any light entering it. It also enabled it to be wiped clean if required. This was designed to
be a prototype hence the materials involved (Figure 1).
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cohort size), which were analysed using an i-Raman portable Raman system with BAC100/BAC102 
lab-grade Raman probe from B&W Tek from Pacer International, with software version 4.1. All 
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routine clinical setting. 
Figure 1. The handheld Raman probe in situ in the Neuropathology Department at Royal Preston
Hospital. ( I stru ent setup showing (1) Ram n probe, (2) sample compart ent, (3) Raman detector
and laser source, and (4) computer module with appropriate software. (b) A different vi w of the
instrument setup with the sample compartmen opened. (c) Sample holder with an example slide
inside the sample compartment.
Integrating such studies in a typical clinical setting is a major challenge, especially during such
serious and complicated procedures. Fresh brain tissue samples sent to the laboratory for intraoperative
smear preparations were tested over a 6-month period (Table 1). Ethical approval was obtained from
the BTNW brain bank (NRES14/EE/1270). We obtained n = 29 samples (a decent cohort size), which
were analysed using an i-Raman portable Raman system with BAC100/BAC102 lab-grade Raman
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probe from B&W Tek from Pacer International, with software version 4.1. All consented samples
arriving in the laboratory were tested over a six-month time period, typical of a routine clinical setting.
Table 1. Results of both intraoperative smear preparations and final formalin-fixed paraffin-embedded
tissue for each case tested.
Case Number Smear Result Paraffin Result
1 Low-grade glioma Glioblastoma
2 Meningioma Meningioma
3 Metastasis Ovarian serous carcinoma
4 High-grade glioma Glioblastoma
5 High-grade glioma Glioblastoma
6 Meningioma Meningioma
7 Metastasis Adenocarcinoma
8 High-grade glioma Glioblastoma
9 High-grade glioma Glioblastoma
10 Metastasis Renal cell carcinoma
11 Metastasis Lung adenocarcinoma
12 no tumour Glioblastoma
13 Low-grade glioma Astrocytoma Grade 2
14 Inflammation Astrocytoma Grade 2
15 Inflammation Astrocytoma Grade 2
16 Metastasis Ovarian serous carcinoma
17 High-grade glioma Glioblastoma
18 High-grade glioma Glioblastoma
19 High-grade glioma Glioblastoma
20 High-grade glioma Glioblastoma
21 High-grade glioma Glioblastoma
22 reactive Low-grade glioma Low grade glioma
23 Intermediate-grade glioma Glioblastoma
24 Low-grade glioma Astrocytoma Grade 3
25 Lymphoma High grade B cell lymphoma
26 Glioma Astrocytoma Grade 2
27 No definite tumour Astrocytoma Grade 2
28 Low- to intermediate-grade glioma Astrocytoma Grade 2
29 High-grade glioma Glioblastoma
The samples tested using the Raman spectrometer were obtained from tissue sent for
intraoperative smear diagnosis. This tissue was then formalin fixed along with any remaining tissue for
formal neuropathological examination. The sample arrived via air-tube from theatre within 5–10 min of
removal from the patient. Prior to sample analysis, a small amount of tissue (similar in size to that used
for a smear preparation) [20] was placed onto a glass slide covered with aluminium foil [21] and 100 µL
of 5 µg/mL BioPureTM 20 nm gold nanoparticles diluted in PBS was dropped onto the sample and left
for 2 min to absorb prior to collecting 10 spectra per sample. Gold nanoparticles were used to enhance
spectral quality. Each spectrum had an acquisition time of 30 s at a laser power of 75%, field of view
0.9 mm × 0.9 mm, with a 785 nm laser. In total the spectra took 5 min to acquire and 2 min to save prior
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to analysis. This equates to the time taken to prepare a smear preparation prior to histopathological
analysis. Once analysed tissue was formalin-fixed for final histopathological diagnosis.
Data analysis was then conducted using MATLAB R2014b software (MathWorks Inc., Natick, MA,
USA) with an IRootlab toolkit [22]. The raw spectral data were initially pre-processed by cutting the
region of interest, 1800–400 cm−1, followed by polynomial baseline correction and vector normalisation.
Thereafter, principal component analysis-linear discriminant classifier (PCA-LDC) was applied for
classification of the datasets on a spectral basis. The training and validation sets were split using
sub-dataset generation specification algorithm within IRootlab toolkit, where the model validation was
performed using 10% of samples randomly assigned to the validation set during model construction.
Due to the small number of samples, each spectrum was analysed separately for a predicted tissue
pathology. PCA-LDC uses PCA as feature extraction method, where the original data is decomposed
into a few number of principal components (PCs) representing the majority of the information in the
original dataset. The scores on each PC are then used as input variables for linear discriminant analysis
(LDA). LDA works by maximizing the between-class variance over the within-class variance in order to
create a linear decision boundary between the classes that provides the optimum class segregation [23].
Patient factors, including the location of the tumour and biopsy were not considered within this study.
Whilst the tumour site does influence the histopathological diagnosis, many pathologists prefer to
start the diagnostic process on morphology only, blinded to demographics, history and site to prevent
unconscious bias. Once a morphological diagnosis or range of differential diagnoses are formulated
this can be tested against the site and demographics. Therefore, the Raman analysis is essentially being
used to offer the same initial analysis as a pathologist on morphology only. Demographics, history
and site are part of the secondary analysis, which as this study develops in the future could then be
included within the analysis.
3. Results
Over the 29 samples from 27 patients, 290 spectra were collected and analysed. Due to the
relatively small number of samples, each spectrum was analysed separately for a predicted tissue
pathology. From this, PCA-LDC was employed and receiver operating characteristic (ROC) curves
generated. This was done to determine the classification accuracies of the Raman spectra as compared
to both the intraoperative smear result and final FFPE histological diagnosis, followed by ROC curves
to determine the accuracy of the classification model as well as its sensitivity and specificity were
generated. Low-grade gliomas were considered WHO grades 1 and 2, and high-grade gliomas WHO
grades 3 and 4. Meningiomas were classed as WHO grade 1. Metastatic tumours were grouped due to
the range of different primary sites within the tumours tested, and as intraoperatively ‘metastasis’ is
sufficient for intraoperative surgical planning. The Raman spectra with or without gold nanoparticles
for the same type of sample (high-grade glioma) are shown in Figure 2a. SERS is emitted from only
the molecules adsorbed on the nanoparticles surface; thus the spectrum is not always the same as the
corresponding Raman spectrum without nanoparticles. In our case, although the shape of both spectra
looks similar, the Raman spectrum with gold nanoparticles contains higher intensities in the regions
between ~1300–1700 cm−1 and ~700–1000 cm−1. Figure 2b depicts the Raman spectra for non-tumour
brain and cancer (high-grade glioma) tissue samples in presence of gold nanoparticles.
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3.1. SERS Results Compared to Intraoperative Smear Preparation
From Figure 3 it can be seen that the accuracy for detection of primary brain tumours was
between 64% and 92%. The algorithm provided the lowest accuracy for meningioma (64%) with
differentiation of glial tumours proving more robust (92.2 and 89.7%). The ROC parameters and curves
(Figure 4, Table 2) demonstrate the sensitivities and specificities range from 64%–94% and 91%–100%,
respectively, again with meningioma falling behind the ther tumours for sensitivity. As t e area
under the curve is >0.8 for all tumour cl ssifications t confirms the hig accuracy f the classification
model and presence f statistical significance (P < 0.001). T is is an important result if this mod l is to
provide clinically useful information. With the exception of meningioma the positive and negative
predictive values are consistently high (Table 2), with all negative predictive values over 95%.
Biosensors 2019, 9, x FOR PEER REVIEW 6 of 13 
 
Figure 2. Baseline-corrected Raman spectra for (a) high-grade glioma tissues with and without gold 
nanoparticles (NP); (b) none tumour (normal) brain and cancer (high-grade glioma) tissues with gold 
nanoparticles. Each spectrum represents the average of 10 measurements in the tissue sample. 
3.1. SERS Results Compared to Intraoperative Smear Preparation 
From Figure 3 it can be seen that the accuracy for detection of pri ary brain tumours was 
between 64% and 92%. The algorithm provided the lowest accuracy for meningioma (64%) with 
differentiation of glial tumours proving more robust (92.2 and 89.7%). The ROC parameters and 
curves (Figure 4, Table 2) demonstrate the sensitiviti s and specificities range from 64%–94% and 
91%–100%, respectively, again with meni gioma falling behind the other tumours for sensitivity. As 
the area under the curve is >0.8 for all tumour classifications it confirms the high accuracy of the 
classification model and presence of statistical significance (P <0.001). This is an important result if 
this model is to provide clinically useful information. With the exception of meningioma the positive 
and negative predictive values are consistently high (Table 2), with all negative predictive values 
over 95%. 
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Met: Metastasis, Ly; Lymphoma. Green demonstrates those correctly classified, whereas red indicates
an incorrect classification.
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Figure 4. Receiver operating characteristic curves for smear-based samples: (a) Low-grade Glioma;
(b) High-grade Gli ma; (c) Meningioma; (d) Metastasis; (e) Lymphoma; and, (f) Non tumour brain
tissue. Dashed pale blue curves represent 95% confidence intervals (AUC: area under the curve).
Table 2. Figures of merit for PCA-LDC model using smear-based samples. Cohen’s kappa coefficient
(κ) = 0.87.
Class Accuracy (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
N 98.6 94.4 99.5 97.7 98.8
LG 96.1 92.2 97.0 88.7 98.0
HG 90.3 89.7 90.6 83.5 94.4
Men 94.8 63.9 97.1 62.1 97.3
Met 95.4 79.2 8.8 93.3 95.8
Lv 99.6 88.9 100 100 99.6
Key: N; Non-tumour brain tissue, LG; Low-grade Glioma, HG; High-grade Glioma, Men; Meningioma,
Met: Metastasis, Ly; Lymphoma, PPV; positive predictive value, NPV; negative predictive value.
3.2. SERS Results Compared to FFPE Tissue Results
When comparing the SERS results to the final FFPE diagnosis, the classification model also works
with a high degree of accuracy. With the exception of metastatic tumours, the accuracy dips slightly for
all cases as compared to the smear results (Figure 5, Table 3). This may be due to a variety of reasons,
including non-tumour brain tissue within the biopsy material or areas of necrosis. Given this is not
possible to determine macroscopically by eye, this remains a limitation of the study. The reduction
in classification accuracy is to be expected as the neuropathologist has many diagnostic tools to
aid the final FFPE diagnosis such as tumour morphology, architecture and immunohistochemical
testing. The ROC graphs though do continue to show the reliability and statistical significance of the
classification odel (Figure 6), highlighting the ability of SERS to differentiate the tumour types within
this study. Following formalin fixation all samples were found to contain tumour tissue therefore no
non-tumour samples are represented within this analysis.
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Met: Metastasis, Ly; Lymphoma. Green demonstrates those correctly classified, whereas red indicates
an incorrect classification.
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Table 3. Figures of merit for PCA-LDC model using paraffin-embedded tissue results. Cohen’s kappa
coefficient (κ) = 0.85.
Class Accuracy (%) Sensitivity (%) S ecificity (%) PPV (%) NPV (%)
LG 93.8 88.7 95.4 85.8 96.4
HG 88.0 82.8 92.8 91.6 85.1
Men 90.8 91.7 90.8 42.4 99.3
Met 96.3 78.7 100 100 95.7
Lv 99.5 86.1 100 100 99.5
Key: LG; Low-grade Glioma, HG; High-grade Glioma, Men; Meningioma, Met: Metastasis, Ly; Lymphoma, PPV;
positive predictive value, NPV; negative predictive value.
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4. Discussion
Many Raman spectroscopic studies have been performed in recent years with the aim of
introducing a clinically useful diagnostic tool that is easy to use and reagent-free. Much work has been
performed towards standardisation of methodology and analysis, as this has previously led to criticism
as many different techniques have been used [24]. Previous work within the field has shown good
discrimination between normal and cancerous tissue. For example, within brain tumours, prostate and
ovarian cancer we have previously found potential using Raman spectroscopy to differentiate normal
from tumour within both tissue and biofluids [5,25–27]. The aim of this study was to determine if a
handheld Raman probe could provide comparable results to both an intraoperative smear preparation
and the final FFPE histological diagnosis. Comparable results would allow for further exploration of a
Raman based probe for intraoperative use, particularly within the field of neuro-oncology. The use
of fresh tissue, within a neuropathology laboratory, testing samples sent for smear preparations
demonstrates a novel approach within this field, moving spectroscopic assessment closer to the patient.
This study was designed to be a snap-shot of a typical clinical setting in a neuro-oncology surgical
department over a 6-month period in order to ascertain the potential of extending our investigations
into the potential translatability of this approach for routine practice.
These results demonstrate the ability of a handheld Raman device, when combined with gold
nanoparticles, to differentiate tumour types from fresh brain tissue. The results are comparable to
both the intraoperative smear preparations and final FFPE diagnosis, with accuracy at detecting
a variety of primary brain tumours and metastases ranging from 63.9–94.4% as compared to the
intraoperative smear preparation, and 78.7–91.7% when compared to the FFPE diagnosis. With the
exception of meningioma the sensitivities and specificities are above 75% throughout, with the majority
over 90%. The PPV and NPV results are also consistently high. It is possible that the meningioma
group demonstrated lower accuracies due to varying morphological appearances. A much larger
study would be required to determine differences between meningiomas of different types and grade.
A similar issue applies to metastasis. This is a difficult group to combine as they are from different
primary sites and therefore a different phenotype which will be expressed and would likely account
for the differences in spectral classification. Due to the small number of metastatic tumours it was
not possible to sub-classify these based on spectra within this study. This would be a next step when
taking this study forward into a larger test group. These results are also comparable to a recent study
demonstrating the possible use of Raman to detect tumours prior to biopsy [14]. For a test to be
clinically useful, especially intraoperatively, a high accuracy, PPV and NPV is needed. These results
compare well to a study performed on intraoperative smears and the final results compared to the
FFPE diagnosis, which yielded an accuracy of 95.25% with PPV of 95.3% and NPV of 95.1% [28].
This is an important step as it allows the results to be comparative to current techniques, possibly
demonstrating an improvement. By adequately training the Raman probe these results demonstrate a
possible improvement on the current method of intraoperative smear diagnosis, reducing the human
element involved and decreasing time to reach a diagnosis. As the accuracy of the Raman probe
is slightly reduced when results are compared to the FFPE diagnosis for the majority of tumours
(see Figures 3 and 5), the role for conventional neuropathology remains, with this tool focused towards
intraoperative diagnosis. As this technique is taken forward, it would also require improvements
within the Raman spectrometer to reduce the signal to noise ratio, in order for the nanoparticles to
no longer be required, as one of the leading benefits to spectroscopy is the lack of labelling required.
They were however felt to be important to this study given it is an early step in the introduction of
spectroscopy into a surgical theatre.
These positive findings indicate the possible benefits to having a handheld Raman device present
within the neurosurgical theatre, although much larger datasets need to be explored before clinical
trial, in particular for classes that had a small number of samples in this study, such as lymphoma and
metastasis. As all tissue was preserved following spectral acquisition and fixed to aid final diagnosis,
we have also shown that spectral acquisition and addition of nanoparticles have not harmed the tissue,
Biosensors 2019, 9, 49 10 of 12
nor prevented final histological diagnosis as a final diagnosis by a Consultant Neuropathologist was
possible in all cases. This is an important step when bringing this technology into the clinical field.
Patient factors were not considered within this study as they were felt unlikely to directly influence
the histopathological assessment. As the technique is developed, it may prove useful to add patient
characteristics into an algorithm to improve accuracy, particularly within the paediatric field as some
tumours are inherent to certain age groups.
When comparing these results to the final FFPE, it is understood that a final histopathological
diagnosis includes many factors, including molecular analysis. The comparison was performed within
this study to demonstrate differences primarily between an intraoperative result and the FFPE. Further
studies would be required to determine if the Raman spectral differences were able to differentiate the
underlying molecular changes, thus circumventing the need for molecular testing.
These results would suggest a handheld device within theatres, may be able to assist surgeons in
removing tumour tissue without the need for an intraoperative smear preparation. This could reduce
surgical time as no result is awaited and allow for improved surgical resection as small foci of tumour
could be identified. It can be seen that the time taken to prepare and take the spectra is similar to that
required to produce a smear preparation, therefore the time saved is within the analysis and removal
of the need to send the sample to the pathology laboratory. Moving this study forward, it would be
important to study the junction between non-tumour brain tissue, brain tissue infiltrated by tumour
cells and tumour tissue to understand the threshold at which the Raman probe is able to detect tumour
cells. This would therefore allow demonstration of any benefit of its use over current methods.
As the classification model is able to determine tumour type this also would allow for further
management steps to be completed, such as the addition of Gliadel wafers in the case of high-grade
gliomas. The use of intracranial chemotherapy, such as Gliadel, is recommended by the National
Institute for Clinical Excellence (NICE) under certain conditions, one of which is the diagnosis
intraoperatively of a high-grade glioma by a neuropathologist [29]. Raman spectroscopy could therefore
be used to circumvent the need to involve the neuropathologist, streamlining processes within theatre.
The identification of a metastatic tumour is also important when planning the level of resection
undertaken. We have not used the results to determine primary tumour origin for metastatic tumours,
as this has previously been shown to be challenging, particularly for cases such as adenocarcinomas
from different primary sites [30]. Intraoperatively, the determination of a metastasis versus a primary
brain tumour is the level required and offered from an intraoperative smear preparation. Therefore
allowing conventional histopathology and immunohistochemistry to determine the primary site of
origin is the most logical step.
Determination of surgical margins within breast cancer has been demonstrating using Raman
spectroscopy [19]. If developed, our classification model may also allow for other surgical sites to
determine presence of absence of tumour intraoperatively, again removing the need for intraoperative
frozen sections to be performed and improve resection clearance. Additional information such as
samples descriptive statistics (e.g., age, gender and tumour location) would benefit the interpretation
of the analysis results to provide a more patient-driven diagnosis. Herein, these factors were not
considered, which limits this paper to the specific features of the cohort analysed. Nevertheless,
Raman spectroscopy combined with chemometric algorithms has shown great potential for tumour
differentiation, evidenced on the high accuracies, sensitivities and specificities achieved for this data set.
5. Conclusions
Overall, this study presents a novel approach to intraoperative brain tumour diagnosis and is
one of the first studies to report results on intraoperative fresh brain tumour samples. The next step
is to move this technology into theatre and continue to develop the classification model to allow for
real-time feedback to the surgeon and allow Raman technology to reach its full potential.
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